Outer Biosciences now feeds live human skin—harvested from discarded surgical tissue and kept viable for more than a month—into machine-learning models. The startup hopes to make drug-discovery and dermatology predictions far more reliable. Its two-year pipeline moves tissue from operating rooms to a lab within hours, a speed the company says preserves the cells’ natural behavior.
Why the old data-sets fall short
For most of biotech’s recent history, researchers have relied on animal models or cultured cell lines to train computational tools. Those systems are cheap and easy to handle, but they rarely capture the full complexity of human skin—a layered organ with immune cells, nerve endings, microbiome interactions and a dynamic response to hormones and stress. The mismatch forces drug developers to run multiple rounds of animal testing and human trials, inflating costs and extending timelines.
Outer Biosciences positions itself as a bridge across that gap. By using tissue that has never been altered in a dish, the company believes its AI can learn patterns invisible to synthetic models. “Living data” is the phrase the team uses to describe the difference between a static snapshot of a cell line and a continuously interacting tissue slice that still communicates with its environment.
From the operating room to the algorithm
The logistical challenge matches the scientific one. Outer Biosciences sources skin that would otherwise be discarded during procedures such as abdominoplasties or mastectomies. Nonprofit and commercial biobanks, operating under Institutional Review Board (IRB) oversight, document donor consent for research use. Once a hospital flags a suitable specimen, the company’s courier network picks it up, transports it in temperature-controlled containers, and delivers it to a processing facility within a few hours.
In the lab, the skin sits in a perfusion system that mimics blood flow, keeping the cells alive for up to 30 days. During that window, the team captures high-resolution imaging, transcriptomics and proteomics data at multiple time points. The multi-modal dataset feeds deep-learning pipelines that predict how the tissue will react to chemical compounds, UV exposure, or inflammatory triggers.
The people pulling the lever
Co-founder and CEO Michael Polansky brings a mathematics background from Harvard and a track record of scaling complex operations, from venture-capital portfolios to global concert tours. Chief Scientist Kyung-Jin Jang, a skin-biology specialist, directs the experimental side, while CTO Chris Hinojosa builds the data-engineering platform that stitches together imaging and molecular streams. The board includes pop-culture icon Lady Gaga, who also chairs the cosmetics brand Haus Labs, a venture that shares research resources with Outer Biosciences.
These cross-industry ties give the startup both the capital to build a niche logistics network and a ready market for early applications. Haus Labs, for example, could test new formulations on the live-tissue platform before moving to human volunteers, potentially shaving weeks off the typical product-development cycle.
What’s at stake
If the approach lives up to its promise, pharmaceutical companies could cut the number of animal studies required for early-stage screening, reducing both cost and ethical concerns. Dermatology clinics might gain AI tools that predict how a patient’s skin will respond to a prescription cream, enabling truly personalized treatment plans. The broader AI community could also benefit from a richer, more realistic training set that pushes the limits of predictive biology.
The model raises questions about scalability and privacy. Collecting tissue from surgery depends on hospitals and donors willing to participate, and the supply chain may bottleneck as demand rises. While biobanks operate under IRB oversight, detailed molecular profiles could, in theory, be linked back to individuals if data-handling practices slip. Critics argue that even with consent, the commercial exploitation of discarded tissue skirts a thin ethical line.
Counter-point: Do organoids still have a role?
オルガノイド（臓器の機能を模倣するためにラボで培養された、細胞の三次元クラスター）を開発する科学者たちは、それらのモデルを完全に排除することに対して警鐘を鳴らしている。オルガノイドは、単一の患者の人工多能性幹細胞（iPS細胞）から生成することができ、新鮮な外科組織を必要とせずにパーソナライズされたプラットフォームを提供できる。また、オルガノイドは研究者が数ヶ月にわたって発生プロセスを研究することを可能にするが、これは30日間の皮膚切片では不可能なことである。Outer Biosciencesは、自社のプラットフォームが普遍的な代替手段ではなく、皮膚の本来の構造が最も重要となる特定の問いに対して、高精度なデータを提供する補完的なリソースであることを認めている。
今後の展望
Outer Biosciencesは現在、複数のバイオテクノロジーパートナーとパイロット研究を実施しており、既知の薬物結果に対して自社モデルの予測力をテストしている。内部ブリーフィングでのみ共有されている初期結果によれば、従来のオルガノイドベースの予測よりも、臨床試験データとの高い相関性が示唆されている。同社は組織の収集範囲を他の臓器タイプにも拡大する計画だが、それぞれに特有のロジスティクス上の課題が伴うことになる。
規制当局は、生体ヒト組織でトレーニングされたAIモデルに関する具体的なガイダンスをまだ発行していないが、FDAが策定を進めているAI駆動型医療機器向けの枠組みは、Outer社の取り組みと交差することになるだろう。同スタートアップは、データプライバシー基準と、アルゴリズムの透明性に関する当局の期待の両方を満たす文書を準備していると述べている。
結論
Outer Biosciencesは、手術室からラボへ新鮮なヒト皮膚を数時間以内に移動させるというロジスティクス上の難題を、薬物や皮膚の健康に関するAIの予測をより信頼性の高いものにするデータエンジンへと変貌させた。このベンチャーの成功は、組織の供給ラインを維持し、ドナーのプライバシーを保護し、「リビングデータ」が既存の合成モデルを実際に凌駕することを証明できるかどうかにかかっている。もしそれが実現すれば、その波及効果は製薬、化粧品、臨床皮膚科の分野全体に及び、人体を理解するための機械の学習方法を再構築することになるだろう。